Jasper Therapeutics, Inc. JSPR

Company Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted conditioning therapies for hematopoietic stem cell transplantation (HSCT), gene therapy, and treatment of chronic autoimmune diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on antibody-based therapeutics designed to selectively deplete stem cells and immune cells while reducing the toxicities associated with traditional conditioning regimens such as chemotherapy and radiation. Its lead product candidate, briquilimab (formerly JSP191), is an anti-CD117 monoclonal antibody intended for use across multiple disease settings.

The company’s principal revenue driver has historically been collaboration and licensing activity rather than commercial product sales, as it remains in the clinical development stage. Jasper Therapeutics primarily serves healthcare providers, transplant centers, gene therapy developers, and patients with rare diseases and immune-mediated conditions. The company’s strategic positioning is based on the potential for targeted conditioning approaches to improve transplant outcomes and expand eligibility for stem cell and gene therapies. Jasper Therapeutics was founded in 2018 and became publicly traded through a merger with a special purpose acquisition company in 2021, after which it expanded clinical development efforts around briquilimab and related therapeutic applications.

Business Operations

Jasper Therapeutics’ operations are centered around the development of its proprietary anti-CD117 platform, with briquilimab representing the company’s primary clinical asset. The company focuses on disease indications including severe combined immunodeficiency (SCID), chronic spontaneous urticaria, mast cell-driven diseases, and conditioning regimens for stem cell transplantation and gene therapy. Revenue generation remains limited and primarily consists of licensing agreements, collaboration arrangements, and financing activities typical of development-stage biotechnology companies. The company does not currently market approved commercial products.

Operationally, Jasper Therapeutics conducts clinical trials in the United States and collaborates with external contract research organizations, manufacturers, and academic institutions. The company controls intellectual property related to CD117-targeted conditioning technologies and monoclonal antibody development. Public filings identify relationships with clinical research partners and manufacturing vendors supporting biologics development and trial execution. Data regarding large-scale joint ventures or material operating subsidiaries is inconclusive based on available public sources.

Strategic Position & Investments

Jasper Therapeutics’ strategic direction is focused on advancing briquilimab across multiple therapeutic categories while demonstrating that targeted conditioning can replace or reduce reliance on conventional cytotoxic conditioning approaches. The company has prioritized clinical programs involving stem cell transplantation, gene therapy conditioning, and mast cell depletion therapies. Its growth strategy includes expanding indications for briquilimab, pursuing regulatory advancement through clinical trials, and leveraging the antibody platform in areas where safer conditioning regimens could improve patient access and outcomes.

The company has invested significantly in clinical development, manufacturing scale-up, and regulatory activities tied to briquilimab. Public disclosures indicate a focus on rare diseases and immunology-related disorders where unmet medical need remains high. Jasper Therapeutics has also explored opportunities involving emerging cell and gene therapy ecosystems, particularly where conditioning regimens are a limiting factor for broader adoption. Available public filings do not identify a broad portfolio of subsidiaries or major acquisition activity comparable to larger biotechnology firms.

Geographic Footprint

Jasper Therapeutics is headquartered in Redwood City, California, and its primary operational footprint is concentrated in the United States. Clinical development activities are conducted through healthcare institutions, research centers, and clinical trial networks that may include international participation depending on trial design and enrollment requirements. The company’s investor base and regulatory focus are primarily tied to U.S. capital markets and the U.S. Food and Drug Administration.

While Jasper Therapeutics does not maintain the extensive multinational commercial infrastructure typical of large pharmaceutical companies, its therapeutic programs are relevant to global transplant, immunology, and gene therapy markets. The company’s clinical and scientific collaborations contribute to its presence within broader biotechnology ecosystems across North America and selected international research environments. Data regarding significant standalone operational infrastructure outside the United States is limited in public disclosures.

Leadership & Governance

Jasper Therapeutics is led by an executive team with backgrounds in biotechnology development, clinical medicine, immunology, and capital markets. The company’s governance structure follows the standards applicable to publicly traded U.S. biotechnology companies, including oversight by a board of directors and executive leadership responsible for clinical strategy, finance, operations, and regulatory execution. Leadership communications have emphasized advancing targeted conditioning approaches designed to improve safety and accessibility for stem cell transplantation and gene therapy.

Key executives identified in recent public filings include:

• Ron Martell – Chief Executive Officer
• Christopher Keenan – Chief Financial Officer
• Shane Olwill, Ph.D. – Chief Development Officer
• Leslie M. Williams – Chairperson of the Board

Information in this overview is based on publicly available disclosures including SEC filings, company investor materials, and reporting from established financial and biotechnology industry publications. Where public information was limited or inconsistent, this has been noted accordingly.